Ahsan Chaudhry
Overview
Explore the profile of Ahsan Chaudhry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Puckrin R, Kinzel M, Stewart D, Chaudhry A, Jamani K, Storek J
Transplant Cell Ther
. 2025 Jan;
31(3):176.e1-176.e8.
PMID: 39761871
Multiple factors have been described to influence the risk of acute or chronic graft-versus-host disease (aGVHD or cGVHD) after allogeneic hematopoietic cell transplantation (HCT), including underlying chronic myeloid leukemia (CML)...
2.
Puckrin R, Kwan A, Blosser N, Leyshon C, Duggan P, Daly A, et al.
Cytotherapy
. 2023 Jun;
25(10):1101-1106.
PMID: 37306643
Background Aims: Although calcineurin inhibitors (CNIs) have a well-established role in the prevention of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), their use can be limited by significant...
3.
Khanolkar R, Tripathi G, Dharmani-Khan P, Dabas R, Kinzel M, Kalra A, et al.
Cytotherapy
. 2022 Sep;
24(12):1225-1231.
PMID: 36057497
Background Aims: The value of routine chimerism determination after myeloablative hematopoietic cell transplantation (HCT) is unclear, particularly in the setting of anti-thymocyte globulin (ATG)-based graft-versus-host disease (GVHD) prophylaxis. Methods: Blood...
4.
Nunez L, Abedin T, Naqvi S, Shen H, Chaudhry A, Bellerby S, et al.
Blood Adv
. 2022 Jan;
6(3):767-773.
PMID: 34995342
Subsequent malignancies (SMs) present a significant burden of morbidity and are a common cause of late mortality in survivors of allogeneic hematopoietic cell transplant (allo-HCT). Previous studies have described total...
5.
Storek J, Kanji J, Choi M, Kalra A, Chaudhry A, Jamani K, et al.
Bone Marrow Transplant
. 2021 Oct;
57(1):119-121.
PMID: 34616007
No abstract available.
6.
Kinzel M, Dowhan M, Kalra A, Williamson T, Dabas R, Jamani K, et al.
Transplant Cell Ther
. 2021 Oct;
28(1):53.e1-53.e10.
PMID: 34607072
Post-transplant lymphoproliferative disorder (PTLD) is a potentially serious complication that occurs following hematopoietic cell transplantation (HCT), in which B cells transformed by Epstein-Barr virus (EBV) proliferate uncontrollably. It is unknown...
7.
Khanolkar R, Kalra A, Kinzel M, Pratt L, Dharmani-Khan P, Chaudhry A, et al.
Cytotherapy
. 2021 Aug;
23(11):1007-1016.
PMID: 34373186
Background Aims: Intensified immunosuppressive prophylaxis for graft-versus-host disease (GVHD) may be toxic and therefore warranted only in patients at high risk of developing GVHD. In patients who underwent allogeneic hematopoietic...
8.
Khan A, Barber D, Huang J, Rupar C, Rip J, Auray-Blais C, et al.
Nat Commun
. 2021 Feb;
12(1):1178.
PMID: 33633114
Enzyme and chaperone therapies are used to treat Fabry disease. Such treatments are expensive and require intrusive biweekly infusions; they are also not particularly efficacious. In this pilot, single-arm study...
9.
Evernden C, Dowhan M, Dabas R, Chaudhry A, Kalra A, Dharmani-Khan P, et al.
Cytotherapy
. 2020 Jan;
22(1):27-34.
PMID: 31889628
Background: International guidelines for Pneumocystis jirovecii pneumonia (PJP) prevention recommend prophylaxis for ≥6 months following allogeneic hematopoietic cell transplantation, and longer in patients with graft-versus-host disease (GVHD) or on immunosuppressive...
10.
Dabas R, Jamani K, Kangarloo S, Dharmani-Khan P, Williamson T, Ousia S, et al.
Blood Adv
. 2019 May;
3(9):1394-1405.
PMID: 31043372
It remains unknown why rabbit antithymocyte globulin (ATG; Thymoglobulin) has not affected relapse after hematopoietic cell transplantation (HCT) in randomized studies. We hypothesized that high pre-HCT ATG area under the...